



4 June 2024

Incanthera plc
("Incanthera" the "Company")

AQSE Webinar Presentation
'Aquis Leading Lights: Meet the Company of the Year 2024 Nominees'

Incanthera plc (AQSE:INC), the company focused on innovative technologies in dermatology and oncology, is pleased to announce that it will be presenting at an Aquis Stock Exchange Webinar, for Small Cap Awards 2024 Nominees.

'Meet the Leading Lights of Aquis Exchange' Webinar will take place at 12.30 pm on 5 June 2024.

Chairman, Tim McCarthy, will be presenting an overview of Incanthera's growth and progression from the company's flotation onto Aquis in February 2020, to the most recent commercial updates, leading to their Nominee as Aquis Company of the Year 2024.

The presentation, which will not contain any inside information, will be made available on the day on the company's website, www.incanthera.com.

Aquis Stock Exchange makes a point of championing entrepreneurship, investment and growth. This webinar will provide an overview of AQSE and give investors and advisors the chance to hear from and interact with the senior management of the nominees for the Aquis Award.

For further information on the event, the Nominees and to Register to see Incanthera's presentation, please click on the link below:

<https://smallcapnetwork.co.uk/event/small-cap-awards-nominees-meet-the-leading-lights-of-aquis-exchange/>

RNS Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained in this announcement is of a non-regulatory nature.

For further information please contact:

Incanthera plc www.incanthera.com	
Tim McCarthy, Chairman tim.mccarthy@incanthera.com	+44 (0) 7831 675747
Simon Ward, Chief Executive Officer simon.ward@incanthera.com	+44 (0) 7747 625506
Suzanne Brocks, Head of Communications suzanne.brocks@incanthera.com	+44 (0) 7776 234600
Broker: Stanford Capital Partners Ltd Patrick Claridge / Bob Pountney	+44 (0) 20 3650 3650/51

Notes to Editors

About Incanthera plc

Incanthera is a specialist company focused on innovative technologies in dermatology and oncology. It seeks to identify and develop innovative solutions to current clinical, commercially relevant unmet needs, utilising new technology from leading specialists

commercially available animal models, deriving from technology from leading scientists and academic institutions as well as its in-house development team.

The Company originated from the Institute of Cancer Therapeutics ("ICT") at the University of Bradford. Incanthera's strategy is to develop each candidate in its portfolio from initial acquisition or discovery to securing its future through commercially valuable partnerships at the earliest opportunity in its development pathway.

For more information on the Company please visit: www.incanthera.com

[@incantherapl](https://twitter.com/incantherapl)

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

NRAEAXKDEAXLEFA